Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 947-948

  Nissen, M J ^a   Boucher, A ^b   Brulhart, L ^c   Menetrey, J ^a   Gabay, C ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c Division of Rheumatology Neuchatel Hospital   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; YTTRIUM;

ADULT; ARTHROSCOPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; JOINT BIOPSY; JOINT SWELLING; KNEE PAIN; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REOPERATION; REPEATED DRUG DOSE; SYNOVECTOMY; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

MAGNETIC RESONANCE IMAGING; SYNOVITIS; TREATMENT; ULTRASONOGRAPHY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INJECTIONS, INTRA-ARTERIAL; KNEE JOINT; MALE; RECURRENCE; SYNOVITIS, PIGMENTED VILLONODULAR; YOUNG ADULT;

EID: 84898007389     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204589     Document Type: Letter

References (10)

1. Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum 2011;40:539-46.
2. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol 2011;23:361-6.
3. Sharma V, Cheng EY. Outcomes after excision of pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 2009;467:2852-8.
4. Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee. Arthroscopy 2001;17:527-31.
5. Griffin AM, Ferguson PC, Catton CN,, et al Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery. Cancer 2012;118:4901-9.
6. Koca G, Ozsoy H, Atilgan HI,, et al A low recurrence rate is possible with a combination of surgery and radiosynovectomy for diffuse pigmented villonodular synovitis of the knee. Clin Nucl Med 2013;38:608-15.
7. van der Bijl AE, Teng YK, van Oosterhout M, et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum 2009;61:974-8.
8. West RB, Rubin BP, Miller MA,, et al A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 2006;103:690-5. (Pubitemid 43153087)
9. Cupp JS, Miller MA, Montgomery KD,, et al Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 2007;31:970-6. (Pubitemid 47165154)
10. Curry JM, Eubank TD, Roberts RD,, et al M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 2008;3:e3405